Ticagrelor Tarbis 90 mg film-coated tablets EFG

Patient Information Leaflet

Introduction

Patient Information Leaflet

Ticagrelor Tarbis 90 mg film-coated tablets EFG

Read the entire leaflet carefully before you start taking this medicine, because it contains important information for you.

• Keep this leaflet, as you may need to read it again.
• If you have any questions, ask your doctor or pharmacist.
• This medicine has been prescribed for you only, and you should not give it to others, even if they have the same symptoms as you, because it could harm them.
• If you experience any adverse effects, consult your doctor or pharmacist, even if they are adverse effects not listed in this leaflet. See section 4.

Leaflet Contents

1. What Ticagrelor Tarbis is and what it is used for
2. What you need to know before taking Ticagrelor Tarbis
3. How to take Ticagrelor Tarbis
4. Possible side effects
5. How to store Ticagrelor Tarbis
6. Contents of the pack and other information

1. What Ticagrelor Tarbis is and what it is used for

What Ticagrelor Tarbis is

Ticagrelor Tarbis contains an active substance called ticagrelor. It belongs to a group of medicines known as antiplatelet agents.

What Ticagrelor Tarbis is used for

Ticagrelor, in combination with acetylsalicylic acid (another antiplatelet agent), is intended for use in adults only. You have been prescribed this medicine because you have had:

• a myocardial infarction (heart attack), or
• unstable angina (chest pain or discomfort not adequately controlled).

This medicine reduces the risk of having another heart attack, stroke, or dying from a heart- or blood vessel-related disease.

How Ticagrelor Tarbis works

Ticagrelor acts on blood cells called 'platelets' (also known as thrombocytes). These small blood cells help stop bleeding by clumping together to plug small holes in blood vessels that are cut or damaged.

However, platelets can also form clots inside damaged blood vessels in the heart and brain. This can be very dangerous because:

• the clot may completely block blood flow, which can lead to a heart attack (myocardial infarction) or stroke, or
• the clot may partially block blood vessels supplying the heart, reducing blood flow to the heart and causing intermittent chest pain (known as 'unstable angina').

Ticagrelor helps prevent platelets from clumping together. This reduces the likelihood of forming a blood clot that could restrict blood flow.

2. What you need to know before taking Ticagrelor Tarbis

Do not take Ticagrelor Tarbis if:

• You are allergic to ticagrelor or to any of the other ingredients of this medicine (listed in section 6).
• You are currently experiencing bleeding.
• You have had a stroke caused by bleeding in the brain.
• You have severe liver disease.
• You are taking any of the following medicines:
  • ketoconazole (used to treat fungal infections)
  • clarithromycin (used to treat bacterial infections)
  • nefazodone (an antidepressant)
  • ritonavir and atazanavir (used to treat HIV infection and AIDS)

Do not take Ticagrelor if any of the above apply to you. If you have any doubts, consult your doctor or pharmacist before taking this medicine.

Warnings and precautions

Talk to your doctor or pharmacist before taking this medicine if:

• You have an increased risk of bleeding due to:
  • a recent serious injury
  • a recent surgical procedure (including dental procedures; consult your dentist about this)
  • a disorder affecting blood clotting
  • recent bleeding from the stomach or intestines (such as a stomach ulcer or colon ‘polyps’)
• You are scheduled to undergo surgery (including dental procedures) at any time while taking Ticagrelor. This is because the risk of bleeding may increase. Your doctor may decide to stop treatment with this medicine 5 days before surgery.
• Your heart rate is abnormally slow (usually less than 60 beats per minute) and you do not already have a device implanted to regulate your heart rhythm (pacemaker).
• You have asthma or other lung problems or difficulty breathing.
• You develop irregular breathing patterns, such as periods of faster, slower, or brief pauses in breathing. Your doctor will decide whether further evaluation is needed.
• You have had liver problems or a previous illness that may have affected your liver.
• You have had a blood test showing elevated levels of uric acid.

If any of the above apply to you (or if you are unsure), consult your doctor or pharmacist before taking this medicine.

If you are taking Ticagrelor and heparin:

• Your doctor may require a blood sample for diagnostic testing if heparin-induced thrombocytopenia (a rare platelet disorder caused by heparin) is suspected. It is important to inform your doctor that you are taking both Ticagrelor and heparin, as Ticagrelor may affect the diagnostic test.

Children and adolescents

Ticagrelor is not recommended for use in children and adolescents under 18 years of age.

Other medicines and Ticagrelor Tarbis

Tell your doctor or pharmacist if you are taking, have recently taken, or might need to take any other medicines. This is because Ticagrelor may affect how some medicines work, and some medicines may affect Ticagrelor.

Inform your doctor or pharmacist if you are taking any of the following medicines:

• Rosuvastatin (a medicine used to treat high cholesterol)
• more than 40 mg daily of simvastatin or lovastatin (medicines used to treat high cholesterol levels)
• rifampicin (an antibiotic)
• phenytoin, carbamazepine, and phenobarbital (used to control epileptic seizures)
• digoxin (used to treat heart failure)
• cyclosporine (used to suppress the body’s immune system)
• quinidine and diltiazem (used to treat abnormal heart rhythms)
• beta-blockers and verapamil (used to treat high blood pressure)
• morphine and other opioids (used to treat acute pain)

In particular, inform your doctor or pharmacist if you are taking any of the following medicines that increase the risk of bleeding:

• ‘Oral anticoagulants’, often referred to as ‘blood thinners’, including warfarin.
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), commonly taken as painkillers, such as ibuprofen and naproxen.
• Selective Serotonin Reuptake Inhibitors (SSRIs), taken as antidepressants, such as paroxetine, sertraline, and citalopram.
• Other medicines such as ketoconazole (used to treat fungal infections), clarithromycin (used to treat bacterial infections), nefazodone (an antidepressant), ritonavir and atazanavir (used to treat HIV infection and AIDS), cisapride (used to treat stomach acid), and ergot alkaloids (used to treat migraines and headaches).

Also inform your doctor that, because you are taking Ticagrelor, you may have an increased risk of bleeding if you are given fibrinolytic agents, often called ‘clot busters’, such as streptokinase or alteplase.

Pregnancy and breastfeeding

The use of Ticagrelor is not recommended if you are pregnant or could become pregnant. Women should use appropriate contraceptive methods to prevent pregnancy while taking this medicine.

Consult your doctor before taking this medicine if you are breastfeeding. Your doctor will explain the benefits and risks of taking this medicine during this period.

If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before taking this medicine.

Driving and using machines

It is unlikely that Ticagrelor will affect your ability to drive or operate machinery. However, if you feel dizzy or confused while taking this medicine, take care when driving or using machines.

Ticagrelor Tarbis contains sodium

This medicine contains less than 1 mmol of sodium (23 mg) per tablet, i.e., essentially ‘sodium-free’.

3. How to take Ticagrelor Tarbis

Follow exactly the administration instructions for this medicine as indicated by your doctor. If in doubt, consult your doctor or pharmacist again.

How much to take

• The initial dose is two tablets at once (loading dose of 180 mg). This dose is normally administered in the hospital.
• After this initial dose, the usual dose is one 90 mg tablet twice daily for 12 months, unless your doctor tells you otherwise.
• Take this medicine at the same time every day (for example, one tablet in the morning and one at night).

Taking Ticagrelor Tarbis with other blood-thinning medicines

Your doctor will usually also prescribe acetylsalicylic acid. This is a substance found in many medicines used to prevent blood clotting. Your doctor will tell you how much to take (usually between 75–150 mg daily).

How to take Ticagrelor Tarbis

• You may take this medicine with or without food.

If you have difficulty swallowing the tablet

If you have difficulty swallowing the tablet, you may crush it and mix it with water as follows:

• Crush the tablet into a fine powder.
• Pour the powder into half a glass of water.
• Stir and drink immediately.
• To ensure no medicine remains, rinse the empty glass with another half glass of water and drink it.

If you are in hospital, this tablet may be administered mixed with a small amount of water through a tube inserted through the nose (nasogastric tube).

If you take more Ticagrelor Tarbis than you should

If you take more Ticagrelor than you should, consult your doctor or go to hospital immediately. Take the medicine packaging with you. You may have an increased risk of bleeding.

In case of overdose or accidental ingestion, consult your doctor or call the Toxicology Information Service at telephone 91 562 04 20, indicating the medicine and the amount ingested.

If you forget to take Ticagrelor Tarbis

• If you forget to take a dose, simply take your next dose at the usual time.
• Do not take a double dose (two doses at once) to make up for forgotten doses.

If you stop taking Ticagrelor Tarbis

Do not stop taking this medicine without consulting your doctor. Take this medicine regularly and for the full duration indicated by your doctor. If you stop taking Ticagrelor, your risk of having another heart attack or stroke, or of dying from a heart or blood vessel-related disease, may increase.

If you have any further questions about using this medicine, ask your doctor or pharmacist.

4. Possible adverse effects

Like all medicines, this medicine can cause adverse effects, although not everyone experiences them. The following adverse effects may occur with this medicine:

Ticagrelor affects blood clotting, so most adverse effects are related to bleeding. Bleeding may occur anywhere in the body. Some degree of bleeding is common (such as bruising and nosebleeds). Serious bleeding is uncommon but can potentially be life-threatening.

Contact your doctor immediately if you notice any of the following – you may need urgent medical treatment:

• Bleeding in the brain or within the skull is an uncommon adverse effect, and may cause signs of stroke such as:

  • sudden numbness or weakness in the arms, legs, or face, especially if affecting only one side of the body
  • sudden confusion, difficulty speaking or understanding others
  • sudden difficulty walking or loss of balance or coordination
  • sudden dizziness or sudden severe headache of unknown cause

• Signs of bleeding such as:

  • severe or uncontrollable bleeding
  • unexpected bleeding or bleeding that lasts a long time
  • pink, red, or brown urine
  • vomiting blood or vomit that looks like "coffee grounds"
  • black or red stools (resembling tar)
  • coughing or vomiting blood

• Fainting (syncope)

  • temporary loss of consciousness due to a sudden drop in blood flow to the brain (common)

• Signs of a blood clotting disorder called Thrombotic Thrombocytopenic Purpura (TTP) such as:

  • fever and purple spots (called purpura) on the skin and in the mouth, with or without yellowing of the skin or eyes (jaundice), unexplained extreme fatigue or confusion

Contact your doctor if you notice any of the following:

• Shortness of breath – this is very common. It may be due to heart disease or another cause, or it may be a side effect of Ticagrelor. Shortness of breath related to Ticagrelor is usually mild and is characterized by a sudden, unexpected need for air, typically occurring at rest, and may appear during the first weeks of treatment. In many cases, it may resolve on its own. If you think your shortness of breath has worsened or persists, inform your doctor. Your doctor will decide whether you need treatment or further investigations.

Other possible adverse effects

Very common (may affect more than 1 in 10 people)

• High level of uric acid in the blood (as seen in blood tests)
• Bleeding due to blood disorders

Common (may affect up to 1 in 10 people)

• Bruising
• Headache
• Dizziness or sensation of spinning
• Diarrhea or indigestion
• Feeling unwell (nausea)
• Constipation
• Rash
• Itching
• Severe joint pain and swelling – these are signs of gout
• Dizziness, lightheadedness, or blurred vision – these are signs of low blood pressure
• Nosebleeds
• Heavier bleeding than usual after surgery or cuts (e.g., while shaving) and wounds
• Bleeding from the stomach lining (ulcer)
• Bleeding gums

Uncommon (may affect up to 1 in 100 people)

• Allergic reaction – skin rash, itching, or swelling of the face or swelling of the lips/tongue may be signs of an allergic reaction
• Confusion
• Vision problems caused by bleeding in the eye
• Heavier vaginal bleeding, or bleeding occurring at different times than your usual menstrual period
• Bleeding into joints and muscles causing painful swelling
• Blood in the ear
• Internal bleeding, which may cause dizziness or lightheadedness

Frequency not known (cannot be estimated from available data)

• Abnormally slow heart rate (usually below 60 beats per minute)

Reporting of adverse effects

If you experience any adverse effect, consult your doctor, pharmacist, or nurse, even if it is a possible adverse effect not listed in this leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Medicinal Products: https://www.notificaram.es.

By reporting adverse effects, you can help provide more information on the safety of this medicine.

5. Storage of Ticagrelor Tarbis

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date stated on the packaging, after EXP. The expiry date is the last day of the month indicated.

This medicine does not require any special storage conditions.

Medicines must not be disposed of via wastewater or household waste. Dispose of unused medicines and their containers at a SIGRE point in your pharmacy. If you have any doubts, ask your pharmacist how to dispose of medicines and containers you no longer need. This will help protect the environment.

6. Contents of the pack and other information

Composition of Ticagrelor Tarbis

The active substance is ticagrelor.

Each film-coated tablet contains 90 mg of ticagrelor.

The other components are:

Tablet core: Mannitol (E421), sodium carboxymethyl starch (potato, Type A), povidone K-30 (E1201), microcrystalline cellulose, magnesium stearate (E470b).

Coating: Hypromellose (E464), macrogol 400 (E1521), macrogol 6000 (E1521), talc (E553b), titanium dioxide (E171).

Appearance of the product and contents of the pack

Film-coated tablets, biconvex, round, white to almost white, with an approximate diameter of 9.15 mm, engraved with "70" on one side and "V1" on the other.

Ticagrelor Tarbis is available in blisters containing 14, 50, 56, 60, 100 and 168 film-coated tablets, and in HDPE bottles containing 60 and 180 film-coated tablets.

Only certain pack sizes may be marketed.

Marketing Authorization Holder

Tarbis Farma S.L.

Gran Vía Carlos III, 94

08028 Barcelona

Spain

Manufacturer

Amarox Pharma B.V.

Rouboslaan 32

Voorschoten, 2252TR

The Netherlands

This medicinal product is authorized in the European Economic Area member states under the following names:

Germany: Ticagrelor Amarox 90 mg Filmtabletten

The Netherlands: Ticagrelor Amarox 90 mg, filmomhulde tabletten

Spain: Ticagrelor Tarbis 90 mg film-coated tablets EFG

Date of the most recent revision of this leaflet: January 2025

Detailed information on this medicinal product is available on the website of the Spanish Agency of Medicines and Health Products (AEMPS) http://www.aemps.gob.es/.